Alan B Lancz & Associates Inc. Has $253,000 Stock Position in Sanofi (NASDAQ:SNY)

Alan B Lancz & Associates Inc. lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 13.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,250 shares of the company’s stock after selling 800 shares during the quarter. Alan B Lancz & Associates Inc.’s holdings in Sanofi were worth $253,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Northwest Investment Counselors LLC acquired a new position in Sanofi in the 3rd quarter valued at about $29,000. Concord Wealth Partners boosted its holdings in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the period. Fortitude Family Office LLC grew its position in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares during the last quarter. Sunbelt Securities Inc. increased its stake in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the period. Finally, Versant Capital Management Inc acquired a new stake in Sanofi during the 4th quarter worth approximately $54,000. Institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

Sanofi Price Performance

Shares of Sanofi stock opened at $52.48 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $133.19 billion, a price-to-earnings ratio of 26.78, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a 50-day simple moving average of $48.70 and a two-hundred day simple moving average of $52.19.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the firm earned $2.55 earnings per share. Analysts forecast that Sanofi will post 3.82 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.